Cougar Biotechnology to Present Clinical Data on CB7630 (Abiraterone Acetate) at American Society of Clinical Oncology 2008 Annual MeetingLOS ANGELES--(BUSINESS WIRE)--May 22, 2008 - Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that data from various Phase I and Phase II clinical trials of Cougar's lead drug candidate CB7630 (abiraterone acetate) will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place May 30th through June 3rd in Chicago. Details from both the oral presentations and the poster presentation are as follows: -0-
Poster Presentation Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer. C. P. Carden, F. I. Raynaud, R. L. Jones, S. B. Riggs, V. Martins, N. Oommen, D. McIntosh, G. Lee, J. S. De Bono, F. F. Kabbinavar Abstract #5168, Location: S Hall A1, Saturday, May 31, 8:00 AM - 12:00 PM Oral Presentations Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA). C. J. Logothetis, S. Wen, A. Molina, N. Chieffo, L. A. Smith, P. Troncoso, E. Efstathiou Abstract #5017, Location: W375e, Monday, June 2, 10:00 AM - 10:15 AM Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). C. Ryan, M. R. Smith, J. E. Rosenberg, A. M. Lin, M. Taplin, P. W. Kantoff, V. Huey, J. Kim, E. J. Small Abstract #5018, Location: W375e, Monday, June 2, 10:15 AM - 10:30 AM Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. D. C. Danila, D. E. Rathkopf, M. J. Morris, S. F. Slovin, L. H. Schwartz, K. Farmer, A. Anand, C. Haqq, M. Fleisher, H. I. Scher Abstract #5019, Location: W375e, Monday, June 2, 10:30 AM - 10:45 AM Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). J. S. De Bono, G. Attard, A. H. Reid, C. Parker, M. Dowsett, R. Mollife, T. A. Yap, A. Molina, G. Lee, D. Dearnaley Abstract #5005, Location: W375e, Monday, June 2, 12:00 PM - 12:15 PM
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase III clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. These forward-looking statements include, without limitation, statements related to the benefits to be derived from Cougar's drug development programs, including the potential advantages of CB7630 and its potential for use in the treatment of CRPC and in second-line hormone and chemotherapy treatment settings. Such statements involve risks and uncertainties that could cause Cougar's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization, including the uncertainty of whether results of prior clinical trials of CB7630 will be predictive of results of later stage clinical trials, including COU-AA-301. For a discussion of these and other factors, please refer to Cougar's annual report on Form 10-KSB for the year ended December 31, 2007, as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Cougar undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Cougar Biotechnology, Inc.
Alan H. Auerbach, Chief Executive Officer and President
Mariann Ohanesian, Director of Investor Relations
Russo Partners, LLC
David Schull, +1-212-845-4271
Andreas Marathovouniotis, +1-212-845-4235
Posted: May 2008